Skip to main content
Rize RecoveryThe Newsroom
Science & Medicine· Daily Pulse

JAMA Network Open: 42 Hospital-Addiction Experts Set Consensus on When and How to Start MOUD During an Admission

A peer-reviewed Delphi consensus published May 7 lands the clearest answer yet to a question every hospital is being asked: should we initiate methadone or buprenorphine on the floor, and if so, how?

ByThe Rize NewsroomMay 21, 20261 min readOpioids

JAMA Network Open: 42 Hospital-Addiction Experts Set Consensus on When and How to Start MOUD During an Admission

What landed

A peer-reviewed Delphi consensus paper, led by Yale School of Medicine and published in JAMA Network Open on May 7, brought together 42 national hospital-based addiction-medicine specialists to do something the field has needed for years: a single, authoritative document covering when and how to initiate medications for opioid use disorder (MOUD) during a hospital admission.

The consensus covers four specific clinical scenarios: rapid methadone initiation in patients in withdrawal; low-dose (“micro-induction”) buprenorphine for patients who can’t tolerate traditional inductions; high-dose buprenorphine inductions for patients who can; and the use of long-acting injectable buprenorphine to bridge from inpatient to community. It also addresses adjunctive medications for withdrawal symptom management — clonidine, ondansetron, loperamide — and explicit guidance on how to coordinate the inpatient start with an outpatient methadone clinic or community bupe prescriber.

Why it matters

Hospitals are one of the highest-leverage points in the recovery system. Per the CDC’s MOUD study tracker, patients who start MOUD during a hospitalization have meaningfully better 30- and 90-day retention than those who are referred at discharge without a medication start. The problem has been that individual hospitals — even those with addiction-medicine consult services — have been working from competing internal protocols built around outdated assumptions about precipitated withdrawal.

For Arizona specifically, this is a usable input. The AHCCCS-supported addiction-medicine consult services in Phoenix-area health systems can adopt or cite this consensus directly. It lowers the activation energy for emergency departments and inpatient teams that want to start MOUD but have not had a defensible written protocol to point to. We will update our hospital-based MOUD cluster to reflect the new consensus this week.

Sources Cited

  1. 01.B
    https://medicine.yale.edu/news-article/addiction-experts-develop-best-practices-for-treating-opioid-use-disorder-in-the-hospital/
  2. 02.B
    https://www.cdc.gov/overdose-prevention/data-research/facts-stats/moud-study.html

Filed Under

sciencetreatment

Continue reading

More from this section

Science & Medicine

The Ego Goes Quiet, and So Does the Pattern: What Psychedelics Actually Do to the Psychology of Addiction

Psilocybin suppresses the default mode network. MDMA reduces amygdala reactivity during trauma processing. Ibogaine resets mu-opioid signaling. Here’s what the science says about the psychology of psychedelic therapy for addiction.

Science & Medicine

France Just Approved IV Ketamine for Suicidal Crisis. The US Has an Excuse, Not an Answer.

France’s ANSM became the first national regulator anywhere to authorize IV racemic ketamine for adult acute suicidal crisis. The US approved esketamine in 2019 but won’t standardize IV ketamine—because it’s a generic with no commercial sponsor.

Science & Medicine

The FDA Just Cleared the First US Ibogaine Trial. It Took 30 Years.

DemeRx received FDA IND clearance for noribogaine—an ibogaine metabolite—for alcohol use disorder. Dr. Deborah Mash has been waiting three decades for this regulatory opening.